Project Grant R01HL175045
Award Date
8/1/25
Completion Date
5/31/29
Dollars Obligated
$651K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Providence, RI 02903, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,385,536.00 to Rhode Island Hospital, a division of Lifespan Corporation, to conduct research on pulmonary artery endothelial cell endotypes and the role of anoikis resistance in pulmonary hypertension. The research aims to leverage a novel "cell biopsy" method to define endothelial cell dysfunction in pulmonary arterial hypertension and...
This Project Grant award of $601,507, provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research), aims to elucidate the molecular mechanisms regulating the dynamic nature and interplay between myocardial cell-cell and cell-extracellular matrix (ECM) interactions and the downstream signals that control cardiomyocyte proliferation. The award supports research conducted by Rhode Island Hospital, a division of Lifespan Corporation, to determine the...
This federal Project Grant award of $1,127,798 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to understand the role of macrophages in preserving cardiovascular health and their contributions to cardiovascular disease (CVD). The overarching goal is to identify new therapeutic targets for CVD in both female and male patients. The research will use advanced single cell imaging and omics techniques to characterize harmful...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $528,179 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Miami. The grant supports research to investigate whether extracellular vesicles mediate the systemic effects of ischemia training on monocyte reprogramming, and to determine if regulation of the DHCR24 enzyme in myeloid cells impacts limb perfusion, function, and arteriogenesis in peripheral arterial disease. The research...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,991.40 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arkansas. The grant, effective January 2, 2025 through December 31, 2027, will support the development of microphysiological systems to investigate molecular pathways and cardiomyocyte function in response to hypoxic cardiac injury associated with myocardial infarction and ischemia-reperfusion injury. The project aims to...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research into the role of mitochondrial signaling between cardiomyocytes and fibroblasts in cardiac fibrosis. The $639,621 award, granted on May 15, 2025, will fund a research project led by Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to investigate how intact mitochondria released from cardiomyocytes mediate...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to advance understanding of the role of endothelial epsins in regulating myocardial ischemia and heart regeneration. The $833,681 award to The Children's Hospital Corporation (Boston Children's Hospital) will fund research to decipher the molecular mechanisms by which targeting cardiac endothelial epsins can enhance...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,398,734 to the University of California, Merced to conduct research on understanding the role of the blood vascular system and endothelial cells in early thymus regeneration after cytotoxic treatments. The project aims to utilize novel intravital imaging techniques to directly analyze the live thymus and characterize the impact...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $385,000 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the RU School of Osteopathic Medicine in Pennsylvania. The 5-year grant, which commenced on January 20, 2025, aims to investigate the role of mitochondrial magnesium in regulating mitochondrial calcium uptake and its impact on ischemic reperfusion injury and heart failure. The key objectives are to: 1) define the mechanism by which oxidative stress...
The federal Project Grant award of $621,546.00 was granted on July 20, 2025 by the National Heart Lung and Blood Institute (NHLBI), under the CFDA 93.837 Cardiovascular Diseases Research program. The grant supports research focused on observing the catalytic subunit of cAMP-dependent protein kinase A (PKA-C) at the single molecule level, to understand its role in normal heart function and cardiac disease states. Key objectives include: Engineering a single-walled carbon nanotube field effect...